Clinical Trial

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Study acronym: BECOME
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-15; most recent amendment 2024-07-31.
Status change: Completed → Recruiting 2024-06-04
Trial Details
NCT Number NCT05055908
Lead Sponsor Hunan Province Tumor Hospital
Conditions Lung Cancer
Enrollment 12,000 participants
Start Date 2021-10-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-09-14 (estimated)
Updated on ClinicalTrials.gov 2024-08-02